Luye Pharma
Luye Pharma Group Ltd., commonly referred to as Luye Pharma, is a prominent biopharmaceutical company headquartered in China (CN). Established in 1997, the company has made significant strides in the pharmaceutical industry, focusing on innovative drug development and manufacturing. With a strong presence in major operational regions including Asia, Europe, and North America, Luye Pharma is dedicated to addressing unmet medical needs across various therapeutic areas. The company’s core products encompass a range of advanced formulations, particularly in oncology, central nervous system disorders, and cardiovascular diseases. Luye Pharma is recognised for its unique drug delivery systems, which enhance the efficacy and patient compliance of its therapies. With a commitment to research and development, Luye Pharma has achieved notable milestones, positioning itself as a key player in the global biopharmaceutical market.
DitchCarbon Score
How does Luye Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Luye Pharma's score of 19 is lower than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Luye Pharma's reported carbon emissions
In 2022, Luye Pharma reported total carbon emissions of approximately 78,081,450 kg CO2e, with emissions distributed across Scope 1 and Scope 2. Specifically, Scope 1 emissions included 75,960 kg CO2e from mobile combustion and 2,346,110 kg CO2e from fugitive emissions. Scope 2 emissions comprised 18,980,050 kg CO2e from purchased steam and 48,278,890 kg CO2e from purchased electricity. For 2021, the company recorded total emissions of about 68,537,500 kg CO2e, with similar contributions from Scope 1 and Scope 2 emissions. The trend shows a gradual increase in emissions over the years, with 2020 emissions at approximately 72,087,050 kg CO2e and 2019 at about 63,239,850 kg CO2e. Luye Pharma has not disclosed specific reduction targets or initiatives as part of their climate commitments, indicating a potential area for improvement in their sustainability strategy. The absence of Scope 3 emissions data suggests that the company may not yet be fully addressing its entire carbon footprint. Overall, while Luye Pharma has made strides in emissions reporting, further commitments and reduction strategies would enhance their climate action profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 2,284,540 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | - | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Luye Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
